The EUR/USD exchange rate held steady in the past few months, a trend that may continue in the coming months as top analysts predict a return to US dollar slideThe EUR/USD exchange rate held steady in the past few months, a trend that may continue in the coming months as top analysts predict a return to US dollar slide

EUR/USD forecast as Goldman Sachs predicts a return to dollar slide

2025/12/14 13:52
3 min read
For feedback or concerns regarding this content, please contact us at [email protected]

The EUR/USD exchange rate held steady in the past few months, a trend that may continue in the coming months as top analysts predict a return to US dollar slide amid a divergence between the Federal Reserve and the European Central (ECB). It was trading at 1.1740, much higher than last month’s low of 1.1463.

Top analysts predict a return to US dollar slide 

The EUR/USD pair continued rising as many investors predicted that the US dollar index would start its slide in the coming months.

In several reports, analysts by companies like Goldman Sachs and Deutsche Bank noted that all conditions were highly supportive of a dollar slide.

The main reason is the Federal Reserve will likely maintain a dovish tone as other central banks start hiking interest rates.

For example, analysts believe that the Bank of Japan (BoJ) will hike interest rates this month. Also, the expectation among analysts is that the European Central Bank (ECB) will hike in the third quarter of next year.

Other central banks expected to maintain a hawkish view are the Reserve Bank of Australia (RBA), the People’s Bank of China (PBoC), and the Bank of England (BoE).

On the other hand, the Federal Reserve is expected to maintain a dovish tone in a few months. 

It has already started its quantitative easing (QE) policy, and officials predict that it will deliver one more cut this year. Analysts see the bank cutting rates more times as Donald Trump will replace Jerome Powell with a ‘puppet’.

The only limit to the bank’s Fed cuts will be other officials, who have started dissenting. Three officials dissented in the last meeting, with some voting for a cut and others for a raise.

ECB interest rate decision ahead 

The next key catalyst for the EUR/USD pair will be the upcoming European Central Bank interest rate decision, which will come out on Thursday.

Economists believe that the bank will decide to leave interest rates unchanged in this meeting as the bloc’s economy is doing relatively well and inflation has largely been contained.

As a result, most analysts expect that the bank will hike rates in the third quarter of next year. However, some analysts expect it to cut in March, with a Bloomberg analyst writing:

Therefore, the upcoming monetary policy meeting will shed light on what to expect in the coming meetings. 

EUR/USD technical analysis 

EURUSD chart | Source: TradingView

The EUR/USD exchange rate has been in an uptrend in the past few days, rising from a low of 1.1463 in November to 1.1740 today. It has formed an inverse head-and-shoulders pattern, a popular bullish continuation sign.

The pair has already moved above this pattern’s neckline, a move that has confirmed its uptrend. At the same time, the Relative Strength Index (RSI) and the MACD indicators have continued rising in the past few weeks.

Therefore, we are staring at a situation where the pair may keep rising as bulls target the next key resistance at 1.1913, its highest level this year. A move above that level will point to more gains, potentially to the psychological point at 1.2000.

The post EUR/USD forecast as Goldman Sachs predicts a return to dollar slide appeared first on Invezz

Market Opportunity
EUR Logo
EUR Price(EUR)
$1.1607
$1.1607$1.1607
+0.30%
USD
EUR (EUR) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09